Seville, Spain, April 24, 2024 – Yesterday, April 23, the third meeting of the CAPN12-IO project consortium members took place at the facilities of the Fundación para la Investigación Biomédica del Hospital Universitario Doce de Octubre in Madrid. The meeting was attended by Dr. Paz Ares (i+12), Dr. Santos Mañes and his team (Centro Nacional de Biotecnología (CNB-CSIC)), Dr. Eddy Sotelo and his team (CiQUS – Center for Research in Biological Chemistry and Molecular Materials), as well as representatives of Landsteiner Genmed, the originator and promoter of the project.  The progress of the work carried out during the first year of execution was presented and discussed, and the next stages of the project were defined and agreed upon.

The CAPN12-IO consortium is developing a new oncological immunotherapy aimed at the selective activation of effector cells. It is funded by the Recovery, Transformation and Resilience Plan sponsored by the European Commission and managed by the State Research Agency.

 

Grant CPP2021-009090 funded by MCIN/AEI (10.13039/501100011033) and European Union NextGenerationEU/PRTR.